| 引用本文: | 许高奇,张轶雯,孔思思,郑小卫,何超能,李莉,黄萍.酪氨酸激酶抑制剂的群体药动学研究进展[J].中国现代应用药学,2020,37(15):1899-1906. |
| XU Gaoqi,ZHANG Yiwen,KONG Sisi,ZHENG Xiaowei,HE Chaoneng,LI Li,HUANG Ping.Advances of Population Pharmacokinetics in Tyrosine Kinase Inhibitors[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(15):1899-1906. |
|
| |
|
|
| 本文已被：浏览 47399次 下载 20571次 |
码上扫一扫！ |
|
|
| 酪氨酸激酶抑制剂的群体药动学研究进展 |
|
许高奇1,2, 张轶雯3, 孔思思1,2, 郑小卫1,2, 何超能1,2, 李莉4, 黄萍3
|
|
1.中国科学院大学附属肿瘤医院(浙江省肿瘤医院), 杭州 310022;2.中国科学院肿瘤与基础医学研究所, 杭州 310022;3.浙江省人民医院药剂科, 杭州 310014;4.浙江省淳安县第一人民医院药剂科, 杭州 311700
|
|
| 摘要: |
| 以酪氨酸激酶抑制剂（tyrosine kinase inhibitors，TKIs）为代表的小分子靶向抗肿瘤药物以其高选择性和低毒性等优势已成为肿瘤治疗药物研究的新热点，关于TKIs的群体药动学（population pharmacokinetics，PPK）研究报道也日益增多。本研究综述常见肿瘤TKIs药物的PPK研究进展，列举了各类药物的PPK模型结构参数及其协变量，并总结了药物是否需要根据相关影响因素进行给药方案的调整，以期为临床合理使用TKIs药物及药动-药效学（pharmacokinetic-pharmacodynamics，PK-PD）研究提供参考。 |
| 关键词: 酪氨酸激酶抑制剂 靶向抗肿瘤药物 群体药动学 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.15.020 |
| 分类号:R969.1 |
| 基金项目:浙江省医药卫生科技计划项目（2017KY244，2017RC001，2018KY148） |
|
| Advances of Population Pharmacokinetics in Tyrosine Kinase Inhibitors |
|
XU Gaoqi1,2, ZHANG Yiwen3, KONG Sisi1,2, ZHENG Xiaowei1,2, HE Chaoneng1,2, LI Li4, HUANG Ping3
|
|
1.Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital), Hangzhou 310022, China;2.Institute of Cancer and Basic Medicine(ICBM), Chinese Academy of Sciences, Hangzhou 310022, China;3.Department of Pharmacy, Zhejiang Provincial People's Hospital, Hangzhou 310014, China;4.Department of Pharmacy, the First People's Hospital of Chun'an, Hangzhou 311700, China
|
| Abstract: |
| Small molecule targeted anti-tumor drugs represented by tyrosine kinase inhibitors(TKIs) have become a new hotspot in the research of cancer therapeutic drugs due to their high selectivity and low toxicity, and more and more studies of population pharmacokinetics (PPK) in TKIs are reported. This article summarize the progress of PPK research on TKIs used in common tumor, listed the PPK model structure parameters and covariates, and summarized whether they need to be adjusted according to relevant influencing factors, in order to provide reference for rationally use of TKIs in clinical and pharmacokinetic- pharmacodynamics(PK-PD) studies. |
| Key words: tyrosine kinase inhibitors targeted anti-tumor drugs population pharmacokinetic |
|
|
|
|
